These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28658251)

  • 1. HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial.
    Riddler SA; Husnik M; Ramjee G; Premrajh A; Tutshana BO; Pather A; Siva S; Jeenarain N; Nair G; Selepe P; Kabwigu S; Palanee-Phillips T; Panchia R; Mhlanga F; Levy L; Livant E; Patterson K; Elharrar V; Balkus J
    PLoS One; 2017; 12(6):e0178594. PubMed ID: 28658251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
    Naicker N; Naidoo A; Werner L; Garrett N; Majola N; Asari V; Baxter C; Grobler A; Karim QA; Karim SSA
    Antivir Ther; 2017; 22(4):287-293. PubMed ID: 27835613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.
    Garrett NJ; Werner L; Naicker N; Naranbhai V; Sibeko S; Samsunder N; Gray C; Williamson C; Morris L; Abdool-Karim Q; Abdool-Karim SS
    J Acquir Immune Defic Syndr; 2015 Jan; 68(1):55-61. PubMed ID: 25247433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
    MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
    Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.
    ENCORE1 Study Group
    Lancet; 2014 Apr; 383(9927):1474-1482. PubMed ID: 24522178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring.
    Riddler SA; Balkus JE; Parikh UM; Mellors JW; Akello C; Dadabhai S; Mhlanga F; Ramjee G; Mayo AJ; Livant E; Heaps AL; O'Rourke C; Baeten JM;
    Clin Infect Dis; 2019 Jul; 69(3):523-529. PubMed ID: 30346511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal function of participants in the Bangkok tenofovir study--Thailand, 2005-2012.
    Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Gvetadze RJ; Curlin ME; Leethochawalit M; Chiamwongpaet S; Cherdtrakulkiat T; Anekvorapong R; Leelawiwat W; Chantharojwong N; McNicholl JM; Paxton LA; Kittimunkong S; Choopanya K;
    Clin Infect Dis; 2014 Sep; 59(5):716-24. PubMed ID: 24829212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.
    Weis JF; Baeten JM; McCoy CO; Warth C; Donnell D; Thomas KK; Hendrix CW; Marzinke MA; Mugo N; Matsen FA; Celum C; Lehman DA;
    AIDS; 2016 Jan; 30(1):31-5. PubMed ID: 26731753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir and emtricitabine resistance among antiretroviral-naive patients in the Canadian Observational Cohort Collaboration: implications for PrEP.
    Younger J; Raboud J; Szadkowski L; Harrigan R; Walmsley S; Bayoumi AM; Klein MB; Cooper C; Burchell AN; Loutfy M; Hull M; Wong A; Thomas R; Hogg R; Montaner J; Tsoukas C; Antoniou T;
    Antivir Ther; 2019; 24(3):211-220. PubMed ID: 30873953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis.
    Chirwa LI; Johnson JA; Niska RW; Segolodi TM; Henderson FL; Rose CE; Li JF; Thigpen MC; Matlhaba O; Paxton LA; Brooks JT
    AIDS; 2014 Jan; 28(2):223-6. PubMed ID: 24361682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
    Hazra R; Gafni RI; Maldarelli F; Balis FM; Tullio AN; DeCarlo E; Worrell CJ; Steinberg SM; Flaherty J; Yale K; Kearney BP; Zeichner SL
    Pediatrics; 2005 Dec; 116(6):e846-54. PubMed ID: 16291735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.
    Decloedt EH; Lesosky M; Maartens G; Joska JA
    AIDS Res Ther; 2017 Feb; 14(1):6. PubMed ID: 28160772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
    Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
    Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir-based antiretroviral therapy in 
HBV-HIV coinfection: results from the TREAT Asia HIV Observational Database.
    Boettiger DC; Kerr S; Ditangco R; Chaiwarith R; Li PC; Merati TP; Pham TT; Kiertiburanakul S; Kumarasamy N; Vonthanak S; Lee CK; Van Kinh N; Pujari S; Wong WW; Kamarulzaman A; Zhang F; Yunihastuti E; Choi JY; Oka S; Ng OT; Kantipong P; Mustafa M; Ratanasuwan W; Durier N; Law M;
    Antivir Ther; 2016; 21(1):27-35. PubMed ID: 26069150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.
    Landman R; Koulla-Shiro S; Sow PS; Ngolle M; Diallo MB; Guèye NF; Le Moing V; Eymard-Duvernay S; Benalycherif A; Charpentier C; Peytavin G; Delaporte E; Girard PM;
    Antivir Ther; 2014; 19(1):51-9. PubMed ID: 23970206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis.
    Laeyendecker O; Redd AD; Nason M; Longosz AF; Karim QA; Naranbhai V; Garrett N; Eshleman SH; Abdool Karim SS; Quinn TC
    J Infect Dis; 2015 Sep; 212(5):754-9. PubMed ID: 25712973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial.
    Tan DHS; Raboud JM; Szadkowski L; Grinsztejn B; Madruga JV; Figueroa MI; Cahn P; Barton SE; Clarke A; Fox J; Zubyk W; Walmsley SL;
    J Antimicrob Chemother; 2019 Feb; 74(2):480-488. PubMed ID: 30376108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.